Algernon Pharmaceuticals hits 70% enrollment for Phase 2 clinical study of Ifenprodil for idiopathic pulmonary fibrosis and chronic cough
Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW) has reached 70% of its enrollment target for its Phase 2 clinical study of its re-purposed drug NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough.
The company said the purpose of the 20-patient proof-of-concept Phase 2 human trial is to determine the efficacy of Ifenprodil in the preservation of lung function (including biomarkers of fibrosis), as well as the reduction of associated chronic cough frequency in IPF patients.
As each individual patient enrolls in the study, Algernon said it will begin treatment on an immediate basis for a period of 12 weeks. There are six sites in total participating in the study with four located in Australia and two in New Zealand.
READ: Algernon Pharmaceuticals targets first human study for its DMT stroke program in 4Q 2021
Ifenprodil has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of IPF, and significantly reduced cough frequency and delayed cough onset in a guinea pig acute cough model.
“We are very pleased with the enrollment rate and grateful to the patients who are participating in our IPF and chronic cough Phase 2 clinical study,” said Algernon CEO Christopher Moreau in a statement. “This important research program is one of several being undertaken by Algernon as part of its unique drug re-purposing approach.”
Moreau added the company has about C$3.2 million cash on hand and is expecting a refundable tax credit receivable of C$2 million from the Australian government’s Research & Development Tax Incentive Program in September 2021, making Algernon “well-positioned to continue to execute on its corporate strategy.”
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
Story by ProactiveInvestors
Source: http://www.proactiveinvestors.com/companies/news/954386/algernon-pharmaceuticals-hits-70-enrollment-for-phase-2-clinical-study-of-ifenprodil-for-idiopathic-pulmonary-fibrosis-and-chronic-cough-954386.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).